Fifteen hypertensive patients entered a single-blind study to examine the effects of metoprolol (100 mg twice daily) on fasting plasma lipids. In 12 patients who completed the study, non-esterified fatty acid concentrations fell, but cholesterol and triglyceride levels were unchanged after 12 weeks' treatment. These results conflict with earlier reports of the effect of metoprolol on plasma triglyceride concentrations.
Introduction 3-adrenoreceptor blocking drugs have been reported as having various effects on basal plasma lipid levels. For example, the non-selective drug propranolol has been reported (Tanaka et al., 1976) as reducing plasma non-esterified fatty acids initially, and subsequently, after 7 weeks' treatment, as increasing their concentration. There is conflicting evidence (Waal-Manning, 1976; Nilsson, Hansson and Hdkfelt, 1978) on the effect of the cardioselective 3-adrenoreceptor blocking drug metoprolol on fasting plasma triglyceride concentrations. The present study was designed to observe the effects on fasting plasma lipid levels in hypertensive patients treated with metoprolol for a period of 12 weeks and subsequently to observe the changes over 4 weeks after the withdrawal of treatment.
Patients and methods
Fifteen out-patients (8 male) with uncomplicated essential hypertension were selected for the study. Their ages ranged from 31 to 67 (mean 47) years, and their average blood pressure at the start of the study before treatment with metoprolol was 159/104 mmHg. Eight patients were newly diagnosed and had not received any treatment for hypertension before the study. Of the remaining 7, 4 had previously been treated with a combination of propranolol and bendrofluazide, 2 with hydrallazine and one had Two patients developed tiredness in the metoprolol treatment period which was not apparent in the placebo periods and was therefore thought to be related to metoprolol.
Discussion
There is currently much debate about whether 3-adrenoreceptor blocking drugs or diuretics should be used as first-line treatment for moderate hypertension. The incidence of carbohydrate intolerance after diuretic therapy is significant (Breckenridge et al., 1967) . Diuretics may be associated with a rise in serum cholesterol concentration (Ames and Hill, 1976) . There is evidence that raised triglyceride concentrations increase the risk of cardiovascular death when they exceed 1.7 mmol/l irrespective of the cholesterol concentration (Pelkonen et al., 1977) . Earlier studies (Waal-Manning, 1976 ) using similar doses of metoprolol to those employed in this study had shown that metoprolol increased plasma triglycerides. Clearly if this effect were to be confirmed it would provide a theoretical disadvantage for the use of metoprolol. It is not clear why there should be a discrepancy between the present study and that of Waal-Manning although it has been suggested (Nilsson et al., 1977 (Nilsson et al., , 1978 that such discrepancies might arise from different patient selection criteria. In a study in which patients were investigated under metabolic ward conditions (Nilsson et al., 1978) , metoprolol was found not to affect fasting triglyceride levels nor those values for triglycerides obtained after food and exercise. Propranolol has also been reported as producing no change in triglyceride concentrations (Spottl, Holzknecht and Braunsteiner, 1968) , but that study did show a reduction in free serum cholesterol at the end of 8 weeks' treatment.
Plasma non-esterified fatty acid concentrations have been shown to increase within 24 hr of a myocardial infarction. In non-diabetic patients with myocardial infarction it was found (Spottl et al., 1968) that the plasma concentration of non-esterified fatty acids are significantly higher in those who subsequently develop ventricular fibrillation. Thus, a raised level of non-esterified fatty acids might be potentially harmful in hypertensive patients. Propranolol has been reported (Tanaka et al., 1976) as initially reducing and subsequently increasing nonesterified fatty acid concentrations, atenolol (Deacon, 1978) as reducing them, practolol (Ghosh, Cochrane and de Bono, 1975) as having no effect, while pindolol (Schlierf, Papenberg and Raetzer, 1973) as causing an increase. Metoprolol has previously been reported (Nilsson et al., 1978; Newman, 1977) as having no effect on plasma non-esterified fatty acid levels under basal conditions. The reason for the disparity between the findings in the present study and earlier reports is not clear.
Metoprolol caused a small but significant fall in the serum ablumin concentration. It is unlikely that this was due to a dilutional effect since the serum globulin concentration was not affected. A similar effect has been observed in a study on oxprenolol (Pearson et al., 1976) . Non-esterified fatty acids are avidly bound to albumin (Goodman, 1958) but the relationship is a stoichiometric one. Thus, the reduction in serum albumin (7 %) would not account for the much larger (27 %) reduction in nonesterified fatty acids.
Conclusion
Metoprolol in doses which significantly reduce raised arterial blood pressure has no effect on plasma triglyceride or cholesterol concentrations, but causes a significant reduction in plasma nonesterified fatty acids. This may be of advantage in patients with risk factors for myocardial infarction including those with hypertension.
